An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

NCT ID: NCT01296386

Last Updated: 2014-09-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-12-31
• Study Completion Date: 2013-04-30

Brief Summary

An open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, A new vaccine against Clostridium Difficile (C. difficile), In healthy subjects

Detailed Description

This is an open-label, partially randomized, dose escalation Phase 1 study which will consist of a part A in healthy adults aged between ≥18 and <65 years and a part B in healthy elderly ≥65 years, the latter age group being the most vulnerable population to suffer from C. difficile infections.

Part A consists of 3 vaccinations on Day0, Day7 and Day21 with the following groups:

Group A: IC84 20 mcg (microgram)with Alum Group B: IC84 75 mcg (microgram)with Alum Group C: IC84 75 mcg (microgram)without Alum Group D: IC84 200 mcg(microgram)with Alum Group E: IC84 200 mcg(microgram)without Alum

Part A was already finished and part B is now ongoing. All information which could be find under the other sections are referring to the information on Part B.

Conditions

Clostridium Difficile Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

IC84, 75 µg w/ Alum

75 µg w/ Alum (microgram with Alum)

Group Type: EXPERIMENTAL

IC84

Intervention Type: BIOLOGICAL

IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

IC84, 75 µg w/o Alum

75 µg w/o Alum (microgram without Alum)

Group Type: EXPERIMENTAL

IC84

Intervention Type: BIOLOGICAL

IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

IC84, 200 µg w/ Alum

200 µg w/ Alum (microgram with Alum)

Group Type: EXPERIMENTAL

IC84

Intervention Type: BIOLOGICAL

IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

IC84, 200 µg w/o Alum

200 µg w/o Alum (microgram without Alum)

Group Type: EXPERIMENTAL

IC84

Intervention Type: BIOLOGICAL

IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

Interventions

IC84

IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Healthy adults ≥18 years of age.

2. No clinically relevant pathological findings in any of the investigations at the Screening Visit including subjects with pharmacologically controlled conditions like hypercholesterolemia, hypertension, cardiovascular disease or non insulin-dependent diabetes mellitus. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance.

3. In female subjects, either childbearing potential terminated by surgery or 1 year post menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception.

4. Weight: ≥ 45.5 kg and <= 150 kg at Visit 0 (Screening Visit).

5. White blood cells ≥2,500/mm3 and <11,000/mm3 at Visit 0.

6. Platelets within normal limits at Visit 0.

7. Written informed consent obtained from the subject prior to any study related procedures.

Exclusion Criteria

1. Use of any other investigational or non-registered medicinal product within 30 days prior to IC84 vaccination at Visit 1 (Day 0) and throughout the entire study period.

2. Active or passive vaccination four weeks before first vaccination at Visit 1 and during the entire study period.

3. Immunodeficiency including status post-organ-transplantation or immuno-suppressive therapy, and a family history of congenital or hereditary immunodeficiency.

4. Infection with the human immunodeficiency virus (HIV, a negative test result within 30 days before screening is acceptable), Hepatitis B virus (HBV, Hepatitis B surface antigen [HBsAg]) or Hepatitis C virus (HCV).

5. History of severe hypersensitivity reactions and anaphylaxis.

6. History of allergic bronchial asthma and severe allergic rhinoconjunctivitis.

7. Known hypersensitivity or allergic reactions to one of the components of the vaccine.

8. History of autoimmune disease, including Type I Diabetes mellitus. Subjects with vitiligo or thyroid disease taking thyroid hormone replacement are not excluded.

9. Any malignancy in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled.

10. Clinically significant hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders, which are not adequately controlled by medical treatment within the last 12 weeks before IC84 vaccination at Visit 1 (Day 0) as judged by the site's Principal Investigator.

11. Systemic antibiotic use within four weeks prior to first vaccination and during treatment period (until Day 28).

12. Clinically significant diseases as judged by the investigator.

13. Administration of chronic (defined as longer than 14 days) immunosuppressants or other immune-modifying drugs within 30 days prior to IC84 vaccination at Visit 1 (Day 0) and during the study until Visit 5 (Day 28). (For corticosteroids this means prednisone or equivalent >= 0.05 mg/kg/day; topical and inhaled steroids are allowed.).

14. Periodic steroid injections, e.g., intra-articular, are not allowed within 30 days prior to first IC84 vaccination at Visit 1 (Day 0) and until Visit 5 (Day 28).

15. Intake of NSAID within three days prior to and within three days after all three vaccinations (Day 0, 7 and 21).

16. Acute febrile infections or exacerbation of chronic infection within four weeks prior to first vaccination at Visit 1 and during treatment period (until Day 21).

17. Body temperature > 37°C (oral) immediately prior to each vaccination.

18. Drug addiction within 6 months prior to Visit 0 [including alcohol dependence, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day] indicated by an elevated MCV above normal value at the Screening Visit.

19. Inability or unwillingness to avoid more than the usual intake of alcohol [i.e., not more then 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day] during the 48 hours after vaccination.

20. Pregnancy (positive pregnancy test during screening), lactation or unreliable contraception in female subjects with child-bearing potential ( and unreliable contraception in male subjects.

21. Not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

22. Blood donation within 4 weeks prior to first vaccination.

23. Clinically significant mental disorder not adequately controlled by medical treatment.

24. History of Guillain-Barré-Syndrome (GBS).

25. Any condition which might interfere with study objectives or would limit the subject's ability to complete the study in the opinion of the investigator.

26. Inability or unwillingness to provide informed consent.

27. Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).

• Minimum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Valneva Austria GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrea Ayad, Dr.

Role: STUDY_CHAIR

Valneva Austria GmbH

Locations

Privatklinik Leech

Graz, , Austria

Medizinische Universität Wien

Vienna, , Austria

St. Imre Teaching Hospital

Budapest, , Hungary

Countries

Austria; Hungary

References

Bezay N, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016 May 17;34(23):2585-92. doi: 10.1016/j.vaccine.2016.03.098. Epub 2016 Apr 11.

Reference Type: DERIVED

PMID: 27079932 (View on PubMed)

Other Identifiers

IC84-101

Identifier Type: -

Identifier Source: org_study_id